Lou Bock

Lou Bock is an industry veteran and is focused on identifying emerging biopharmaceutical, device and platform technology companies. Lou sits on the boards of Ascenta Therapeutics, diaDexus, Horizon Therapeutics, Orexigen Therapeutics, SGX Pharmaceuticals and Zogenix. He is responsible for ScaleVP's investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN), and Somaxon (NASDAQ: SOMX).

Lou joined Scale Venture Partners in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead's approved antiviral drug, Vistide, and was responsible for the discovery of Gilead's novel thrombin aptamer. Previous to Gilead, he was a research associate at Genentech.

Lou holds an M.B.A. from California State University, San Francisco and a B.S. in Biology from California State University, Chico.